Current News

Contact | Print version | PDF version | Send article | RSS feed

Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement

25 Jan 2007 - Medarex, Inc. and Compugen Ltd. have entered into a collaborative agreement to develop novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases. Under the terms of the agreement, Medarex and Compugen plan to share discovery, development and commercialization responsibilities on antibody-based therapeutics resulting from this collaboration, and share revenues generated from the sale of such therapeutic products.
 
Under the collaboration, Compugen expects to utilize its proprietary antibody-target discovery engine to identify novel drug targets. Medarex plans to develop fully human antibodies against these targets using its UltiMAb Human Antibody Development System(R). The collaboration also provides that Compugen may independently pursue diagnostic applications involving certain antibodies and targets.